GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curocell Inc (XKRX:372320) » Definitions » Capex-to-Operating-Income

Curocell (XKRX:372320) Capex-to-Operating-Income : 0.00 (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Curocell Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Curocell's Capital Expenditure for the six months ended in Jun. 2023 was ₩-18,588.09 Mil. Its Operating Income for the six months ended in Jun. 2023 was ₩-13,975.25 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Curocell Capex-to-Operating-Income Historical Data

The historical data trend for Curocell's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curocell Capex-to-Operating-Income Chart

Curocell Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
- - - - -

Curocell Semi-Annual Data
Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Income - - - -

Competitive Comparison of Curocell's Capex-to-Operating-Income

For the Biotechnology subindustry, Curocell's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curocell's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curocell's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Curocell's Capex-to-Operating-Income falls into.



Curocell Capex-to-Operating-Income Calculation

Curocell's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-21650.454) / -31129.753
=N/A

Curocell's Capex-to-Operating-Income for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-18588.094) / -13975.252
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curocell  (XKRX:372320) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Curocell Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Curocell's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Curocell (XKRX:372320) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
11, Gukjegwahak 16-ro, Yuseong-gu, Daejeon, KOR, 34002
Curocell Inc is engaged in medical and pharmaceutical research and development. The company is into development of CAR-T treatments that enhance the natural function of immune cells to eliminate cancer cells through genetic manipulation of human immune cells.

Curocell (XKRX:372320) Headlines

No Headlines